Ingrezza Sprinkle

Overview

valbenazine

VMAT2 inhibitor

• CYP2D6 substrate
• CYP3A4 substrate
• P-gp inhibitor, weak
• CNS depression
• increases synaptic monoamines
• prolongs QT interval (conditional)

• add MAO inhibitor to Interaction Check if recent (14 days) use

Contraindicated

• colchicine
Ingrezza Sprinkle (valbenazine)

+

colchicine

1 interaction

Contraindicated

valbenazine + colchicine

CV RISK REDUCTION: consider monitoring CK, myopathy s/sx; GOUT OR FMF: contraindicated in pts w/ renal or hepatic impairment; otherwise, consider decr. colchicine dose during and x14 days after valbenazine use: combo may incr. colchicine levels, risk of myopathy, rhabdomyolysis, other life-threatening toxicity (P-gp-mediated transport inhibited)

• deutetrabenazine
Ingrezza Sprinkle (valbenazine)

+

deutetrabenazine

1 interaction

Contraindicated

valbenazine + deutetrabenazine

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• pimozide
Ingrezza Sprinkle (valbenazine)

+

pimozide

1 interaction

Contraindicated

valbenazine + pimozide

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• quinidine (CYP2D6 inhibitor)
Ingrezza Sprinkle (valbenazine)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Contraindicated

valbenazine + quinidine (CYP2D6 inhibitor)

contraindicated: combo may incr. valbenazine active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• tetrabenazine
Ingrezza Sprinkle (valbenazine)

+

tetrabenazine

1 interaction

Contraindicated

valbenazine + tetrabenazine

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• thioridazine
Ingrezza Sprinkle (valbenazine)

+

thioridazine

1 interaction

Contraindicated

valbenazine + thioridazine

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

Avoid/Use Alternative

• apalutamide
Ingrezza Sprinkle (valbenazine)

+

apalutamide

1 interaction

Avoid/Use Alternative

valbenazine + apalutamide

avoid combo: combo may decr. valbenazine levels. efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• apixaban
Ingrezza Sprinkle (valbenazine)

+

apixaban

1 interaction

Avoid/Use Alternative

valbenazine + apixaban

ADULT PTS: monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban 5mg bid or 10 mg bid dose by 50% or avoid combo if already on 2.5 mg bid; PEDS PTS: monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• arsenic trioxide
Ingrezza Sprinkle (valbenazine)

+

arsenic trioxide

1 interaction

Avoid/Use Alternative

valbenazine + arsenic trioxide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• bedaquiline
Ingrezza Sprinkle (valbenazine)

+

bedaquiline

1 interaction

Avoid/Use Alternative

valbenazine + bedaquiline

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• bosentan
Ingrezza Sprinkle (valbenazine)

+

bosentan

1 interaction

Avoid/Use Alternative

valbenazine + bosentan

avoid combo: combo may decr. valbenazine levels, efficacy (hepatic metab. induced)

• butalbital
Ingrezza Sprinkle (valbenazine)

+

butalbital

1 interaction

Avoid/Use Alternative

valbenazine + butalbital

avoid combo: combo may decr. valbenazine levels, efficacy; may incr. risk of CNS and resp. depression, psychomotor impairment (hepatic metab. induced; additive effects)

• carbamazepine
Ingrezza Sprinkle (valbenazine)

+

carbamazepine

1 interaction

Avoid/Use Alternative

valbenazine + carbamazepine

avoid combo: combo may decr. valbenazine levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• cenobamate
Ingrezza Sprinkle (valbenazine)

+

cenobamate

1 interaction

Avoid/Use Alternative

valbenazine + cenobamate

avoid combo: combo may decr. valbenazine levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• ceritinib
Ingrezza Sprinkle (valbenazine)

+

ceritinib

1 interaction

Avoid/Use Alternative

valbenazine + ceritinib

use alternative or monitor ECG, electrolytes, decr. valbenazine dose to 40 mg qd: combo may incr. valbenazine and active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• cisapride
Ingrezza Sprinkle (valbenazine)

+

cisapride

1 interaction

Avoid/Use Alternative

valbenazine + cisapride

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clonidine
Ingrezza Sprinkle (valbenazine)

+

clonidine

1 interaction

Avoid/Use Alternative

valbenazine + clonidine

if ADHD use, avoid combo; otherwise, caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• codeine
Ingrezza Sprinkle (valbenazine)

+

codeine

1 interaction

Avoid/Use Alternative

valbenazine + codeine

avoid combo if antitussive use; otherwise monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• crizotinib
Ingrezza Sprinkle (valbenazine)

+

crizotinib

1 interaction

Avoid/Use Alternative

valbenazine + crizotinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dabigatran
Ingrezza Sprinkle (valbenazine)

+

dabigatran

1 interaction

Avoid/Use Alternative

valbenazine + dabigatran

ATRIAL FIBRILLATION: avoid combo if CrCl <30 mL/min; OTHER INDICATIONS: avoid combo if CrCl <50 mL/min; if dabigatran use for DVT/PE prophylaxis post-hip replacement and CrCl >50 mL/min, consider separating admin. at least 2h apart: combo may incr. dabigatran levels, risk of bleeding (incl. life-threatening), other adverse effects (P-gp-mediated transport inhibited)

• dabrafenib
Ingrezza Sprinkle (valbenazine)

+

dabrafenib

1 interaction

Avoid/Use Alternative

valbenazine + dabrafenib

avoid combo: combo may decr. valbenazine levels, efficacy (hepatic metab. induced)

• domperidone
Ingrezza Sprinkle (valbenazine)

+

domperidone

1 interaction

Avoid/Use Alternative

valbenazine + domperidone

use alternative or monitor ECG, HR, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• doxylamine
Ingrezza Sprinkle (valbenazine)

+

doxylamine

1 interaction

Avoid/Use Alternative

valbenazine + doxylamine

avoid combo if doxylamine use for pregnancy-related nausea/vomiting, otherwise caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dronedarone
Ingrezza Sprinkle (valbenazine)

+

dronedarone

1 interaction

Avoid/Use Alternative

valbenazine + dronedarone

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• efavirenz
Ingrezza Sprinkle (valbenazine)

+

efavirenz

1 interaction

Avoid/Use Alternative

valbenazine + efavirenz

avoid combo: combo may decr. valbenazine levels. efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• encorafenib
Ingrezza Sprinkle (valbenazine)

+

encorafenib

1 interaction

Avoid/Use Alternative

valbenazine + encorafenib

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. valbenazine levels, efficacy (additive effects; hepatic metab. induced)

• ensartinib
Ingrezza Sprinkle (valbenazine)

+

ensartinib

1 interaction

Avoid/Use Alternative

valbenazine + ensartinib

avoid combo: combo may incr. ensartinib levels, risk of bradycardia, hyperglycemia, other adverse effects (P-gp-mediated transport possibly inhibited)

• enzalutamide
Ingrezza Sprinkle (valbenazine)

+

enzalutamide

1 interaction

Avoid/Use Alternative

valbenazine + enzalutamide

avoid combo: combo may decr. valbenazine levels, efficacy (hepatic metab. induced)

• ephedra
Ingrezza Sprinkle (valbenazine)

+

ephedra

1 interaction

Avoid/Use Alternative

valbenazine + ephedra

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ethanol
Ingrezza Sprinkle (valbenazine)

+

ethanol

1 interaction

Avoid/Use Alternative

valbenazine + ethanol

avoid combo: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• etravirine
Ingrezza Sprinkle (valbenazine)

+

etravirine

1 interaction

Avoid/Use Alternative

valbenazine + etravirine

avoid combo: combo may decr. valbenazine levels, efficacy (hepatic metab. induced)

• fexinidazole
Ingrezza Sprinkle (valbenazine)

+

fexinidazole

1 interaction

Avoid/Use Alternative

valbenazine + fexinidazole

avoid combo during and x7 days after fexinidazole tx; if possible, do not initiate fexinidazole until 5 half-lives after valbenazine D/C: combo may decr. valbenazine levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• fosphenytoin
Ingrezza Sprinkle (valbenazine)

+

fosphenytoin

1 interaction

Avoid/Use Alternative

valbenazine + fosphenytoin

avoid combo: combo may decr. valbenazine levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• futibatinib
Ingrezza Sprinkle (valbenazine)

+

futibatinib

1 interaction

Avoid/Use Alternative

valbenazine + futibatinib

avoid combo if also combined w/ strong CYP3A4 inhibitor; otherwise, monitor phosphate: combo may incr. futibatinib levels, risk of hyperphosphatemia, other adverse effects (P-gp-mediated transport inhibited)

• hydrocodone
Ingrezza Sprinkle (valbenazine)

+

hydrocodone

1 interaction

Avoid/Use Alternative

valbenazine + hydrocodone

avoid combo if antitussive use; otherwise monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• hydroxychloroquine
Ingrezza Sprinkle (valbenazine)

+

hydroxychloroquine

1 interaction

Avoid/Use Alternative

valbenazine + hydroxychloroquine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• isocarboxazid
Ingrezza Sprinkle (valbenazine)

+

isocarboxazid

1 interaction

Avoid/Use Alternative

valbenazine + isocarboxazid

avoid combo w/in 14 days of isocarboxazid use: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment; may decr. valbenazine efficacy (increased synaptic monoamine neurotransmitters, additive effects)

• isoniazid
Ingrezza Sprinkle (valbenazine)

+

isoniazid

1 interaction

Avoid/Use Alternative

valbenazine + isoniazid

avoid combo w/in 14 days of isoniazid use: combo may incr. risk of serotonin syndrome; may decr. valbenazine efficacy (increased synaptic monoamine neurotransmitters; isoniazid inhibits monoamine oxidase)

• ivosidenib
Ingrezza Sprinkle (valbenazine)

+

ivosidenib

1 interaction

Avoid/Use Alternative

valbenazine + ivosidenib

avoid combo: combo may decr. valbenazine levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• kava
Ingrezza Sprinkle (valbenazine)

+

kava

1 interaction

Avoid/Use Alternative

valbenazine + kava

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• kratom
Ingrezza Sprinkle (valbenazine)

+

kratom

1 interaction

Avoid/Use Alternative

valbenazine + kratom

use alternative or monitor resp. rate: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• lefamulin
Ingrezza Sprinkle (valbenazine)

+

lefamulin

1 interaction

Avoid/Use Alternative

valbenazine + lefamulin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• linezolid
Ingrezza Sprinkle (valbenazine)

+

linezolid

1 interaction

Avoid/Use Alternative

valbenazine + linezolid

use alternative or hold valbenazine if urgent use; monitor serotonin syndrome sx x2wk after valbenazine D/C or 24h after last linezolid dose: combo may incr. risk of serotonin syndrome; may decr. valbenazine efficacy (increased synaptic monoamine neurotransmitters; linezolid reversibly inhibits monoamine oxidase)

• lonafarnib
Ingrezza Sprinkle (valbenazine)

+

lonafarnib

1 interaction

Avoid/Use Alternative

valbenazine + lonafarnib

use alternative or monitor HR, ECG, electrolytes; decr. valbenazine dose to 40 mg qd: combo may incr. valbenazine and active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• lopinavir/ritonavir
Ingrezza Sprinkle (valbenazine)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

valbenazine + lopinavir/ ritonavir

avoid combo: combo may incr. or decr. valbenazine levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metab. altered)

• lorlatinib
Ingrezza Sprinkle (valbenazine)

+

lorlatinib

1 interaction

Avoid/Use Alternative

valbenazine + lorlatinib

avoid combo: combo may decr. valbenazine levels, efficacy (hepatic metab. induced)

• lumacaftor/ivacaftor
Ingrezza Sprinkle (valbenazine)

+

lumacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

valbenazine + lumacaftor/ ivacaftor

avoid combo: combo may decr. valbenazine levels, efficacy (hepatic metab. induced)

• mavacamten
Ingrezza Sprinkle (valbenazine)

+

mavacamten

1 interaction

Avoid/Use Alternative

valbenazine + mavacamten

avoid combo: combo may decr. valbenazine levels, efficacy (hepatic metab. induced)

• metaxalone
Ingrezza Sprinkle (valbenazine)

+

metaxalone

1 interaction

Avoid/Use Alternative

valbenazine + metaxalone

use alternative or monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• methylene blue injection
Ingrezza Sprinkle (valbenazine)

+

methylene blue injection

1 interaction

Avoid/Use Alternative

valbenazine + methylene blue injection

hold valbenazine if emergency use; monitor serotonin syndrome sx up to 4h after last methylene blue dose; may resume valbenazine 72h after last methylene blue dose: combo may incr. risk of serotonin syndrome; may decr. valbenazine efficacy (increased synaptic monoamine neurotransmitters; methylene blue reversibly inhibits monoamine oxidase)

• methylene blue oral
Ingrezza Sprinkle (valbenazine)

+

methylene blue oral

1 interaction

Avoid/Use Alternative

valbenazine + methylene blue oral

avoid combo w/in 14 days of methylene blue use: combo may incr. risk of serotonin syndrome; may decr. valbenazine efficacy (increased synaptic monoamine neurotransmitters; methylene blue reversibly inhibits monoamine oxidase)

• metoclopramide
Ingrezza Sprinkle (valbenazine)

+

metoclopramide

1 interaction

Avoid/Use Alternative

valbenazine + metoclopramide

use alternative: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• midazolam
Ingrezza Sprinkle (valbenazine)

+

midazolam

1 interaction

Avoid/Use Alternative

valbenazine + midazolam

use alternative or monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• mitapivat
Ingrezza Sprinkle (valbenazine)

+

mitapivat

1 interaction

Avoid/Use Alternative

valbenazine + mitapivat

avoid combo: combo may decr. valbenazine levels, efficacy (hepatic metab. induced)

• mitotane
Ingrezza Sprinkle (valbenazine)

+

mitotane

1 interaction

Avoid/Use Alternative

valbenazine + mitotane

avoid combo: combo may decr. valbenazine levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• mobocertinib
Ingrezza Sprinkle (valbenazine)

+

mobocertinib

1 interaction

Avoid/Use Alternative

valbenazine + mobocertinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• modafinil
Ingrezza Sprinkle (valbenazine)

+

modafinil

1 interaction

Avoid/Use Alternative

valbenazine + modafinil

avoid combo: combo may decr. valbenazine levels, efficacy (hepatic metab. induced)

• nafcillin
Ingrezza Sprinkle (valbenazine)

+

nafcillin

1 interaction

Avoid/Use Alternative

valbenazine + nafcillin

avoid combo: combo may decr. valbenazine levels, efficacy (hepatic metab. induced)

• neratinib
Ingrezza Sprinkle (valbenazine)

+

neratinib

1 interaction

Avoid/Use Alternative

valbenazine + neratinib

avoid combo if also combined w/ strong-mod CYP3A4 inhibitor; otherwise, caution advised: combo may incr. neratinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• oxybate
Ingrezza Sprinkle (valbenazine)

+

oxybate

1 interaction

Avoid/Use Alternative

valbenazine + oxybate

use alternative or monitor resp. rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension, syncope (additive effects)

• pacritinib
Ingrezza Sprinkle (valbenazine)

+

pacritinib

1 interaction

Avoid/Use Alternative

valbenazine + pacritinib

avoid combo: combo may decr. valbenazine levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• pentobarbital
Ingrezza Sprinkle (valbenazine)

+

pentobarbital

1 interaction

Avoid/Use Alternative

valbenazine + pentobarbital

avoid combo: combo may decr. valbenazine levels, efficacy; may incr. risk of CNS and resp. depression, psychomotor impairment (hepatic metab. induced; additive effects)

• pexidartinib
Ingrezza Sprinkle (valbenazine)

+

pexidartinib

1 interaction

Avoid/Use Alternative

valbenazine + pexidartinib

avoid combo: combo may decr. valbenazine levels, efficacy (hepatic metab. induced)

• phenelzine
Ingrezza Sprinkle (valbenazine)

+

phenelzine

1 interaction

Avoid/Use Alternative

valbenazine + phenelzine

avoid combo w/in 14 days of phenelzine use: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment; may decr. valbenazine efficacy (increased synaptic monoamine neurotransmitters, additive effects)

• phenobarbital
Ingrezza Sprinkle (valbenazine)

+

phenobarbital

1 interaction

Avoid/Use Alternative

valbenazine + phenobarbital

avoid combo: combo may decr. valbenazine levels, efficacy; may incr. risk of CNS and resp. depression, psychomotor impairment (hepatic metab. induced; additive effects)

• phenytoin
Ingrezza Sprinkle (valbenazine)

+

phenytoin

1 interaction

Avoid/Use Alternative

valbenazine + phenytoin

avoid combo: combo may decr. valbenazine levels, efficacy; may incr. risk of CNS depression, psychomotor impairment (hepatic metab. induced; additive effects)

• pralsetinib
Ingrezza Sprinkle (valbenazine)

+

pralsetinib

1 interaction

Avoid/Use Alternative

valbenazine + pralsetinib

use alternative or consider monitoring ECG, electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, decr. to 300 mg qd; if on pralsetinib 400 mg qd and also combined w/ strong CYP3A4 inhibitor: decr. to 200 mg qd; if on pralsetinib 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)

• primidone
Ingrezza Sprinkle (valbenazine)

+

primidone

1 interaction

Avoid/Use Alternative

valbenazine + primidone

avoid combo: combo may decr. valbenazine levels, efficacy; may incr. risk of CNS and resp. depression, psychomotor impairment (hepatic metab. induced; additive effects)

• procarbazine
Ingrezza Sprinkle (valbenazine)

+

procarbazine

1 interaction

Avoid/Use Alternative

valbenazine + procarbazine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment; may decr. valbenazine efficacy (increased synaptic monoamine neurotransmitters, additive effects; procarbazine inhibits monoamine oxidase)

• promethazine
Ingrezza Sprinkle (valbenazine)

+

promethazine

1 interaction

Avoid/Use Alternative

valbenazine + promethazine

use alternative or monitor resp. rate; decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• quizartinib
Ingrezza Sprinkle (valbenazine)

+

quizartinib

1 interaction

Avoid/Use Alternative

valbenazine + quizartinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• rasagiline
Ingrezza Sprinkle (valbenazine)

+

rasagiline

1 interaction

Avoid/Use Alternative

valbenazine + rasagiline

avoid combo w/in 14 days of rasagiline use: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment; may decr. valbenazine efficacy (increased synaptic monoamine neurotransmitters, additive effects)

• relugolix
Ingrezza Sprinkle (valbenazine)

+

relugolix

1 interaction

Avoid/Use Alternative

valbenazine + relugolix

PROSTATE CANCER: may hold relugolix if valbenazine tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before valbenazine; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before valbenazine: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• repotrectinib
Ingrezza Sprinkle (valbenazine)

+

repotrectinib

1 interaction

Avoid/Use Alternative

valbenazine + repotrectinib

avoid combo: combo may decr. valbenazine levels, efficacy; may incr. repotrectinib levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. induced; P-gp-mediated transport inhibited, additive effects)

• rifabutin
Ingrezza Sprinkle (valbenazine)

+

rifabutin

1 interaction

Avoid/Use Alternative

valbenazine + rifabutin

avoid combo: combo may decr. valbenazine levels, efficacy (hepatic metab. induced)

• rifampin
Ingrezza Sprinkle (valbenazine)

+

rifampin

1 interaction

Avoid/Use Alternative

valbenazine + rifampin

avoid combo: combo may decr. valbenazine levels, efficacy (hepatic metab. induced)

• rifapentine
Ingrezza Sprinkle (valbenazine)

+

rifapentine

1 interaction

Avoid/Use Alternative

valbenazine + rifapentine

avoid combo: combo may decr. valbenazine levels, efficacy (hepatic metab. induced)

• rivaroxaban
Ingrezza Sprinkle (valbenazine)

+

rivaroxaban

1 interaction

Avoid/Use Alternative

valbenazine + rivaroxaban

avoid combo if also combined w/ strong CYP3A4 inhibitor; use alternative if CrCl <80 and combined w/ moderate CYP3A4 inhibitor; otherwise, monitor bleeding s/sx: combo may incr. rivaroxaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• safinamide
Ingrezza Sprinkle (valbenazine)

+

safinamide

1 interaction

Avoid/Use Alternative

valbenazine + safinamide

avoid combo w/in 14 days of safinamide use: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment; may decr. valbenazine efficacy (increased synaptic monoamine neurotransmitters, additive effects)

• selegiline
Ingrezza Sprinkle (valbenazine)

+

selegiline

1 interaction

Avoid/Use Alternative

valbenazine + selegiline

avoid combo w/in 14 days of selegiline use: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment; may decr. valbenazine efficacy (increased synaptic monoamine neurotransmitters, additive effects)

• selegiline transdermal
Ingrezza Sprinkle (valbenazine)

+

selegiline transdermal

1 interaction

Avoid/Use Alternative

valbenazine + selegiline transdermal

avoid combo w/in 14 days of selegiline use: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment; may decr. valbenazine efficacy (increased synaptic monoamine neurotransmitters, additive effects)

• sirolimus albumin-bound
Ingrezza Sprinkle (valbenazine)

+

sirolimus albumin-bound

1 interaction

Avoid/Use Alternative

valbenazine + sirolimus albumin-bound

avoid combo: combo may incr. sirolimus albumin-bound levels, risk of serious infection, myelosuppression, bleeding (incl. life-threatening), other adverse effects (P-gp-mediated transport inhibited)

• sotalol
Ingrezza Sprinkle (valbenazine)

+

sotalol

1 interaction

Avoid/Use Alternative

valbenazine + sotalol

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sotorasib
Ingrezza Sprinkle (valbenazine)

+

sotorasib

1 interaction

Avoid/Use Alternative

valbenazine + sotorasib

avoid combo: combo may decr. valbenazine levels. efficacy (hepatic metab. induced)

• St. John's wort
Ingrezza Sprinkle (valbenazine)

+

St. John's wort

1 interaction

Avoid/Use Alternative

valbenazine + St. John's wort

avoid combo: combo may decr. valbenazine levels, efficacy (hepatic metab. induced)

• thalidomide
Ingrezza Sprinkle (valbenazine)

+

thalidomide

1 interaction

Avoid/Use Alternative

valbenazine + thalidomide

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• topotecan
Ingrezza Sprinkle (valbenazine)

+

topotecan

1 interaction

Avoid/Use Alternative

valbenazine + topotecan

avoid combo w/ oral topotecan: combo may incr. topotecan levels, risk of serious infection, myelosuppression, other adverse effects (gut P-gp-mediated transport inhibited)

• toremifene
Ingrezza Sprinkle (valbenazine)

+

toremifene

1 interaction

Avoid/Use Alternative

valbenazine + toremifene

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tranylcypromine
Ingrezza Sprinkle (valbenazine)

+

tranylcypromine

1 interaction

Avoid/Use Alternative

valbenazine + tranylcypromine

avoid combo w/in 14 days of tranylcypromine use: combo may incr. risk of serotonin syndrome, CNS depression, psychomotor impairment; may decr. valbenazine efficacy (increased synaptic monoamine neurotransmitters, additive effects)

• trimethobenzamide
Ingrezza Sprinkle (valbenazine)

+

trimethobenzamide

1 interaction

Avoid/Use Alternative

valbenazine + trimethobenzamide

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• vandetanib
Ingrezza Sprinkle (valbenazine)

+

vandetanib

1 interaction

Avoid/Use Alternative

valbenazine + vandetanib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• venetoclax
Ingrezza Sprinkle (valbenazine)

+

venetoclax

1 interaction

Avoid/Use Alternative

valbenazine + venetoclax

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (P-gp-mediated transport inhibited)

• yohimbe
Ingrezza Sprinkle (valbenazine)

+

yohimbe

1 interaction

Avoid/Use Alternative

valbenazine + yohimbe

avoid combo w/in 14 days of yohimbe use: combo may incr. risk of serotonin syndrome; may decr. valbenazine efficacy (increased synaptic monoamine neurotransmitters; yohimbe inhibits monoamine oxidase)

• ziprasidone
Ingrezza Sprinkle (valbenazine)

+

ziprasidone

1 interaction

Avoid/Use Alternative

valbenazine + ziprasidone

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• zuranolone
Ingrezza Sprinkle (valbenazine)

+

zuranolone

1 interaction

Avoid/Use Alternative

valbenazine + zuranolone

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

Monitor/Modify Tx

• adagrasib
Ingrezza Sprinkle (valbenazine)

+

adagrasib

1 interaction

Monitor/Modify Tx

valbenazine + adagrasib

monitor ECG, electrolytes; decr. valbenazine dose to 40 mg qd: combo may incr. valbenazine and active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• afatinib
Ingrezza Sprinkle (valbenazine)

+

afatinib

1 interaction

Monitor/Modify Tx

valbenazine + afatinib

decr. afatinib dose by 10 mg/day if not tolerated: combo may incr. afatinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• aldesleukin
Ingrezza Sprinkle (valbenazine)

+

aldesleukin

1 interaction

Monitor/Modify Tx

valbenazine + aldesleukin

withhold aldesleukin if mod-severe somnolence occurs; otherwise, caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• alfentanil
Ingrezza Sprinkle (valbenazine)

+

alfentanil

1 interaction

Monitor/Modify Tx

valbenazine + alfentanil

monitor BP, resp. rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension (additive effects)

• alprazolam
Ingrezza Sprinkle (valbenazine)

+

alprazolam

1 interaction

Monitor/Modify Tx

valbenazine + alprazolam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• amiodarone
Ingrezza Sprinkle (valbenazine)

+

amiodarone

1 interaction

Monitor/Modify Tx

valbenazine + amiodarone

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• anagrelide
Ingrezza Sprinkle (valbenazine)

+

anagrelide

1 interaction

Monitor/Modify Tx

valbenazine + anagrelide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• apomorphine
Ingrezza Sprinkle (valbenazine)

+

apomorphine

1 interaction

Monitor/Modify Tx

valbenazine + apomorphine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• artemether/lumefantrine
Ingrezza Sprinkle (valbenazine)

+

artemether/ lumefantrine

1 interaction

Monitor/Modify Tx

valbenazine + artemether/ lumefantrine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• asenapine
Ingrezza Sprinkle (valbenazine)

+

asenapine

1 interaction

Monitor/Modify Tx

valbenazine + asenapine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• atazanavir
Ingrezza Sprinkle (valbenazine)

+

atazanavir

1 interaction

Monitor/Modify Tx

valbenazine + atazanavir

monitor ECG; decr. valbenazine dose to 40 mg qd: combo may incr. valbenazine and active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• atorvastatin
Ingrezza Sprinkle (valbenazine)

+

atorvastatin

1 interaction

Monitor/Modify Tx

valbenazine + atorvastatin

monitor CK, myopathy sx: combo may incr. atorvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (P-gp-mediated transport inhibited)

• azithromycin
Ingrezza Sprinkle (valbenazine)

+

azithromycin

1 interaction

Monitor/Modify Tx

valbenazine + azithromycin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• baclofen intrathecal
Ingrezza Sprinkle (valbenazine)

+

baclofen intrathecal

1 interaction

Monitor/Modify Tx

valbenazine + baclofen intrathecal

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• buprenorphine
Ingrezza Sprinkle (valbenazine)

+

buprenorphine

1 interaction

Monitor/Modify Tx

valbenazine + buprenorphine

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• bupropion
Ingrezza Sprinkle (valbenazine)

+

bupropion

1 interaction

Monitor/Modify Tx

valbenazine + bupropion

monitor ECG; decr. valbenazine dose to 40 mg qd: combo may incr. valbenazine active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• butorphanol
Ingrezza Sprinkle (valbenazine)

+

butorphanol

1 interaction

Monitor/Modify Tx

valbenazine + butorphanol

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• cabozantinib
Ingrezza Sprinkle (valbenazine)

+

cabozantinib

1 interaction

Monitor/Modify Tx

valbenazine + cabozantinib

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• chloramphenicol
Ingrezza Sprinkle (valbenazine)

+

chloramphenicol

1 interaction

Monitor/Modify Tx

valbenazine + chloramphenicol

monitor ECG; decr. valbenazine dose to 40 mg qd: combo may incr. valbenazine and active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• chlordiazepoxide
Ingrezza Sprinkle (valbenazine)

+

chlordiazepoxide

1 interaction

Monitor/Modify Tx

valbenazine + chlordiazepoxide

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• chloroquine
Ingrezza Sprinkle (valbenazine)

+

chloroquine

1 interaction

Monitor/Modify Tx

valbenazine + chloroquine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• chlorpromazine
Ingrezza Sprinkle (valbenazine)

+

chlorpromazine

1 interaction

Monitor/Modify Tx

valbenazine + chlorpromazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• citalopram
Ingrezza Sprinkle (valbenazine)

+

citalopram

1 interaction

Monitor/Modify Tx

valbenazine + citalopram

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• clarithromycin
Ingrezza Sprinkle (valbenazine)

+

clarithromycin

1 interaction

Monitor/Modify Tx

valbenazine + clarithromycin

monitor ECG; decr. valbenazine dose to 40 mg qd: combo may incr. valbenazine and active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• clobazam
Ingrezza Sprinkle (valbenazine)

+

clobazam

1 interaction

Monitor/Modify Tx

valbenazine + clobazam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• clofazimine
Ingrezza Sprinkle (valbenazine)

+

clofazimine

1 interaction

Monitor/Modify Tx

valbenazine + clofazimine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clonazepam
Ingrezza Sprinkle (valbenazine)

+

clonazepam

1 interaction

Monitor/Modify Tx

valbenazine + clonazepam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• clorazepate
Ingrezza Sprinkle (valbenazine)

+

clorazepate

1 interaction

Monitor/Modify Tx

valbenazine + clorazepate

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• cobicistat
Ingrezza Sprinkle (valbenazine)

+

cobicistat

1 interaction

Monitor/Modify Tx

valbenazine + cobicistat

monitor ECG; decr. valbenazine dose to 40 mg qd: combo may incr. valbenazine and active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• cyclosporine
Ingrezza Sprinkle (valbenazine)

+

cyclosporine

1 interaction

Monitor/Modify Tx

valbenazine + cyclosporine

monitor cyclosporine levels, renal fxn: combo may incr. cyclosporine levels, risk of serious infection, nephrotoxicity, other adverse effects (P-gp-mediated transport inhibited)

• dacomitinib
Ingrezza Sprinkle (valbenazine)

+

dacomitinib

1 interaction

Monitor/Modify Tx

valbenazine + dacomitinib

monitor ECG; decr. valbenazine dose to 40 mg qd: combo may incr. valbenazine active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• daridorexant
Ingrezza Sprinkle (valbenazine)

+

daridorexant

1 interaction

Monitor/Modify Tx

valbenazine + daridorexant

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• degarelix
Ingrezza Sprinkle (valbenazine)

+

degarelix

1 interaction

Monitor/Modify Tx

valbenazine + degarelix

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• desflurane
Ingrezza Sprinkle (valbenazine)

+

desflurane

1 interaction

Monitor/Modify Tx

valbenazine + desflurane

monitor ECG, resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS and resp. depression, psychomotor impairment (additive effects)

• desipramine
Ingrezza Sprinkle (valbenazine)

+

desipramine

1 interaction

Monitor/Modify Tx

valbenazine + desipramine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• dexmedetomidine
Ingrezza Sprinkle (valbenazine)

+

dexmedetomidine

1 interaction

Monitor/Modify Tx

valbenazine + dexmedetomidine

monitor HR, ECG, electrolytes; consider decr. dose of one or both drugs: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• dexmedetomidine injection
Ingrezza Sprinkle (valbenazine)

+

dexmedetomidine injection

1 interaction

Monitor/Modify Tx

valbenazine + dexmedetomidine injection

monitor ECG, resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS and resp. depression, psychomotor impairment (additive effects)

• diazepam
Ingrezza Sprinkle (valbenazine)

+

diazepam

1 interaction

Monitor/Modify Tx

valbenazine + diazepam

monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• digoxin
Ingrezza Sprinkle (valbenazine)

+

digoxin

1 interaction

Monitor/Modify Tx

valbenazine + digoxin

monitor digoxin levels, HR; decr. digoxin frequency or dose by 15-30%: combo may incr. digoxin levels, risk of bradycardia, AV block, other adverse effects (P-gp-mediated transport inhibited)

• dihydrocodeine
Ingrezza Sprinkle (valbenazine)

+

dihydrocodeine

1 interaction

Monitor/Modify Tx

valbenazine + dihydrocodeine

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• disopyramide
Ingrezza Sprinkle (valbenazine)

+

disopyramide

1 interaction

Monitor/Modify Tx

valbenazine + disopyramide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dofetilide
Ingrezza Sprinkle (valbenazine)

+

dofetilide

1 interaction

Monitor/Modify Tx

valbenazine + dofetilide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• donepezil
Ingrezza Sprinkle (valbenazine)

+

donepezil

1 interaction

Monitor/Modify Tx

valbenazine + donepezil

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• droperidol
Ingrezza Sprinkle (valbenazine)

+

droperidol

1 interaction

Monitor/Modify Tx

valbenazine + droperidol

monitor ECG; decr. dose of one or both drugs: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• edoxaban
Ingrezza Sprinkle (valbenazine)

+

edoxaban

1 interaction

Monitor/Modify Tx

valbenazine + edoxaban

monitor bleeding s/sx: combo may incr. edoxaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• enfortumab vedotin
Ingrezza Sprinkle (valbenazine)

+

enfortumab vedotin

1 interaction

Monitor/Modify Tx

valbenazine + enfortumab vedotin

if also combined w/ strong CYP3A4 inhibitor, monitor CBC, glucose: combo may incr. enfortumab vedotin levels, risk of myelosuppression, neuropathy, hyperglycemia, other adverse effects (P-gp-mediated transport inhibited)

• epirubicin
Ingrezza Sprinkle (valbenazine)

+

epirubicin

1 interaction

Monitor/Modify Tx

valbenazine + epirubicin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• eribulin
Ingrezza Sprinkle (valbenazine)

+

eribulin

1 interaction

Monitor/Modify Tx

valbenazine + eribulin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• erythromycin
Ingrezza Sprinkle (valbenazine)

+

erythromycin

1 interaction

Monitor/Modify Tx

valbenazine + erythromycin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• esketamine
Ingrezza Sprinkle (valbenazine)

+

esketamine

1 interaction

Monitor/Modify Tx

valbenazine + esketamine

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• estazolam
Ingrezza Sprinkle (valbenazine)

+

estazolam

1 interaction

Monitor/Modify Tx

valbenazine + estazolam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• eszopiclone
Ingrezza Sprinkle (valbenazine)

+

eszopiclone

1 interaction

Monitor/Modify Tx

valbenazine + eszopiclone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ethanol (in some formulations)
Ingrezza Sprinkle (valbenazine)

+

ethanol (in some formulations)

1 interaction

Monitor/Modify Tx

valbenazine + ethanol (in some formulations)

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• etomidate
Ingrezza Sprinkle (valbenazine)

+

etomidate

1 interaction

Monitor/Modify Tx

valbenazine + etomidate

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• everolimus
Ingrezza Sprinkle (valbenazine)

+

everolimus

1 interaction

Monitor/Modify Tx

valbenazine + everolimus

TSC-ASSOC. SEGA, TSC-ASSOC. PARTIAL ONSET SEIZURES, TRANSPLANT: monitor everolimus levels, CBC; OTHER INDICATIONS: monitor CBC: combo may incr. everolimus levels, risk of serious infection, myelosuppression, other adverse effects (P-gp-mediated transport inhibited)

• fentanyl
Ingrezza Sprinkle (valbenazine)

+

fentanyl

1 interaction

Monitor/Modify Tx

valbenazine + fentanyl

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• flecainide
Ingrezza Sprinkle (valbenazine)

+

flecainide

1 interaction

Monitor/Modify Tx

valbenazine + flecainide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluorouracil
Ingrezza Sprinkle (valbenazine)

+

fluorouracil

1 interaction

Monitor/Modify Tx

valbenazine + fluorouracil

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluoxetine
Ingrezza Sprinkle (valbenazine)

+

fluoxetine

1 interaction

Monitor/Modify Tx

valbenazine + fluoxetine

monitor ECG; decr. valbenazine dose to 40 mg qd: combo may incr. valbenazine active metabolite levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, additive effects)

• fluphenazine
Ingrezza Sprinkle (valbenazine)

+

fluphenazine

1 interaction

Monitor/Modify Tx

valbenazine + fluphenazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• flurazepam
Ingrezza Sprinkle (valbenazine)

+

flurazepam

1 interaction

Monitor/Modify Tx

valbenazine + flurazepam

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• gabapentin
Ingrezza Sprinkle (valbenazine)

+

gabapentin

1 interaction

Monitor/Modify Tx

valbenazine + gabapentin

monitor resp. rate: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• gabapentin enacarbil
Ingrezza Sprinkle (valbenazine)

+

gabapentin enacarbil

1 interaction

Monitor/Modify Tx

valbenazine + gabapentin enacarbil

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• gilteritinib
Ingrezza Sprinkle (valbenazine)

+

gilteritinib

1 interaction

Monitor/Modify Tx

valbenazine + gilteritinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• glasdegib
Ingrezza Sprinkle (valbenazine)

+

glasdegib

1 interaction

Monitor/Modify Tx

valbenazine + glasdegib

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• goserelin
Ingrezza Sprinkle (valbenazine)

+

goserelin

1 interaction

Monitor/Modify Tx

valbenazine + goserelin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• haloperidol
Ingrezza Sprinkle (valbenazine)

+

haloperidol

1 interaction

Monitor/Modify Tx

valbenazine + haloperidol

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• histrelin
Ingrezza Sprinkle (valbenazine)

+

histrelin

1 interaction

Monitor/Modify Tx

valbenazine + histrelin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• hydromorphone
Ingrezza Sprinkle (valbenazine)

+

hydromorphone

1 interaction

Monitor/Modify Tx

valbenazine + hydromorphone

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• hydroxyzine
Ingrezza Sprinkle (valbenazine)

+

hydroxyzine

1 interaction

Monitor/Modify Tx

valbenazine + hydroxyzine

monitor ECG; consider decr. hydroxyzine dose: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• ibutilide
Ingrezza Sprinkle (valbenazine)

+

ibutilide

1 interaction

Monitor/Modify Tx

valbenazine + ibutilide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• idelalisib
Ingrezza Sprinkle (valbenazine)

+

idelalisib

1 interaction

Monitor/Modify Tx

valbenazine + idelalisib

monitor ECG; decr. valbenazine dose to 40 mg qd: combo may incr. valbenazine and active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• ifosfamide
Ingrezza Sprinkle (valbenazine)

+

ifosfamide

1 interaction

Monitor/Modify Tx

valbenazine + ifosfamide

D/C one or both drugs if encephalopathy occurs; otherwise, caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• inotuzumab ozogamicin
Ingrezza Sprinkle (valbenazine)

+

inotuzumab ozogamicin

1 interaction

Monitor/Modify Tx

valbenazine + inotuzumab ozogamicin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• isoflurane
Ingrezza Sprinkle (valbenazine)

+

isoflurane

1 interaction

Monitor/Modify Tx

valbenazine + isoflurane

monitor ECG, resp. rate: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS and resp. depression, psychomotor impairment (additive effects)

• itraconazole
Ingrezza Sprinkle (valbenazine)

+

itraconazole

1 interaction

Monitor/Modify Tx

valbenazine + itraconazole

monitor ECG; decr. valbenazine dose to 40 mg qd: combo may incr. valbenazine and active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• ketamine
Ingrezza Sprinkle (valbenazine)

+

ketamine

1 interaction

Monitor/Modify Tx

valbenazine + ketamine

monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression (incl. life-threatening), psychomotor impairment (additive effects)

• ketoconazole
Ingrezza Sprinkle (valbenazine)

+

ketoconazole

1 interaction

Monitor/Modify Tx

valbenazine + ketoconazole

monitor ECG; decr. valbenazine dose to 40 mg qd: combo may incr. valbenazine and active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• landiolol
Ingrezza Sprinkle (valbenazine)

+

landiolol

1 interaction

Monitor/Modify Tx

valbenazine + landiolol

monitor HR, BP: combo may incr. risk of bradycardia, hypotension, incl. orthostasis, syncope (additive effects)

• lemborexant
Ingrezza Sprinkle (valbenazine)

+

lemborexant

1 interaction

Monitor/Modify Tx

valbenazine + lemborexant

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• leuprolide
Ingrezza Sprinkle (valbenazine)

+

leuprolide

1 interaction

Monitor/Modify Tx

valbenazine + leuprolide

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• levofloxacin
Ingrezza Sprinkle (valbenazine)

+

levofloxacin

1 interaction

Monitor/Modify Tx

valbenazine + levofloxacin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• levoketoconazole
Ingrezza Sprinkle (valbenazine)

+

levoketoconazole

1 interaction

Monitor/Modify Tx

valbenazine + levoketoconazole

monitor ECG; decr. valbenazine dose to 40 mg qd: combo may incr. valbenazine and active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• levorphanol
Ingrezza Sprinkle (valbenazine)

+

levorphanol

1 interaction

Monitor/Modify Tx

valbenazine + levorphanol

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• lofexidine
Ingrezza Sprinkle (valbenazine)

+

lofexidine

1 interaction

Monitor/Modify Tx

valbenazine + lofexidine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• lorazepam
Ingrezza Sprinkle (valbenazine)

+

lorazepam

1 interaction

Monitor/Modify Tx

valbenazine + lorazepam

monitor resp. rate, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• macimorelin
Ingrezza Sprinkle (valbenazine)

+

macimorelin

1 interaction

Monitor/Modify Tx

valbenazine + macimorelin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• mavorixafor
Ingrezza Sprinkle (valbenazine)

+

mavorixafor

1 interaction

Monitor/Modify Tx

valbenazine + mavorixafor

monitor ECG; decr. valbenazine dose to 40 mg qd: combo may incr. mavorixafor levels, valbenazine active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• meperidine
Ingrezza Sprinkle (valbenazine)

+

meperidine

1 interaction

Monitor/Modify Tx

valbenazine + meperidine

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• methadone
Ingrezza Sprinkle (valbenazine)

+

methadone

1 interaction

Monitor/Modify Tx

valbenazine + methadone

monitor ECG, resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of QT prolongation, cardiac arrhythmias, profound CNS and resp. depression, psychomotor impairment (additive effects)

• methohexital
Ingrezza Sprinkle (valbenazine)

+

methohexital

1 interaction

Monitor/Modify Tx

valbenazine + methohexital

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• mifepristone
Ingrezza Sprinkle (valbenazine)

+

mifepristone

1 interaction

Monitor/Modify Tx

valbenazine + mifepristone

monitor ECG; decr. valbenazine dose to 40 mg qd during and x14 days after daily mifepristone use; caution advised if pregnancy termination use: combo may incr. valbenazine and active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• mirtazapine
Ingrezza Sprinkle (valbenazine)

+

mirtazapine

1 interaction

Monitor/Modify Tx

valbenazine + mirtazapine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• morphine
Ingrezza Sprinkle (valbenazine)

+

morphine

1 interaction

Monitor/Modify Tx

valbenazine + morphine

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. morphine levels, risk of profound CNS and resp. depression, psychomotor impairment, other adverse effects (P-gp-mediated transport inhibited, additive effects)

• moxifloxacin
Ingrezza Sprinkle (valbenazine)

+

moxifloxacin

1 interaction

Monitor/Modify Tx

valbenazine + moxifloxacin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• nalbuphine
Ingrezza Sprinkle (valbenazine)

+

nalbuphine

1 interaction

Monitor/Modify Tx

valbenazine + nalbuphine

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• nefazodone
Ingrezza Sprinkle (valbenazine)

+

nefazodone

1 interaction

Monitor/Modify Tx

valbenazine + nefazodone

monitor ECG; decr. valbenazine dose to 40 mg qd: combo may incr. valbenazine and active metabolite levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, additive effects)

• nelarabine
Ingrezza Sprinkle (valbenazine)

+

nelarabine

1 interaction

Monitor/Modify Tx

valbenazine + nelarabine

withhold nelarabine if Grade 2 or greater somnolence occurs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• nelfinavir
Ingrezza Sprinkle (valbenazine)

+

nelfinavir

1 interaction

Monitor/Modify Tx

valbenazine + nelfinavir

monitor ECG; decr. valbenazine dose to 40 mg qd: combo may incr. valbenazine and active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• nilotinib
Ingrezza Sprinkle (valbenazine)

+

nilotinib

1 interaction

Monitor/Modify Tx

valbenazine + nilotinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• olanzapine
Ingrezza Sprinkle (valbenazine)

+

olanzapine

1 interaction

Monitor/Modify Tx

valbenazine + olanzapine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, incl. orthostasis (additive effects)

• oliceridine
Ingrezza Sprinkle (valbenazine)

+

oliceridine

1 interaction

Monitor/Modify Tx

valbenazine + oliceridine

monitor resp. rate, ECG, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, hypotension (additive effects)

• ondansetron
Ingrezza Sprinkle (valbenazine)

+

ondansetron

1 interaction

Monitor/Modify Tx

valbenazine + ondansetron

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• opicapone
Ingrezza Sprinkle (valbenazine)

+

opicapone

1 interaction

Monitor/Modify Tx

valbenazine + opicapone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• opium
Ingrezza Sprinkle (valbenazine)

+

opium

1 interaction

Monitor/Modify Tx

valbenazine + opium

monitor resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• osimertinib
Ingrezza Sprinkle (valbenazine)

+

osimertinib

1 interaction

Monitor/Modify Tx

valbenazine + osimertinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• oxazepam
Ingrezza Sprinkle (valbenazine)

+

oxazepam

1 interaction

Monitor/Modify Tx

valbenazine + oxazepam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• oxybutynin
Ingrezza Sprinkle (valbenazine)

+

oxybutynin

1 interaction

Monitor/Modify Tx

valbenazine + oxybutynin

decr. dose of one or both drugs or consider oxybutynin transdermal patch: combo may incr. risk of CNS depression, psychomotor impairment; somnolence less likely w/ oxybutynin transdermal patch (additive effects)

• oxycodone
Ingrezza Sprinkle (valbenazine)

+

oxycodone

1 interaction

Monitor/Modify Tx

valbenazine + oxycodone

monitor resp. rate; decr. oxycodone start dose by at least 50%, consider decr. valbenazine dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• oxymorphone
Ingrezza Sprinkle (valbenazine)

+

oxymorphone

1 interaction

Monitor/Modify Tx

valbenazine + oxymorphone

monitor resp. rate; decr. oxymorphone start dose by at least 50%, consider decr. valbenazine dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• paliperidone
Ingrezza Sprinkle (valbenazine)

+

paliperidone

1 interaction

Monitor/Modify Tx

valbenazine + paliperidone

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• palonosetron
Ingrezza Sprinkle (valbenazine)

+

palonosetron

1 interaction

Monitor/Modify Tx

valbenazine + palonosetron

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• panobinostat
Ingrezza Sprinkle (valbenazine)

+

panobinostat

1 interaction

Monitor/Modify Tx

valbenazine + panobinostat

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• paroxetine
Ingrezza Sprinkle (valbenazine)

+

paroxetine

1 interaction

Monitor/Modify Tx

valbenazine + paroxetine

monitor ECG; decr. valbenazine dose to 40 mg qd: combo may incr. valbenazine active metabolite levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, additive effects)

• pasireotide
Ingrezza Sprinkle (valbenazine)

+

pasireotide

1 interaction

Monitor/Modify Tx

valbenazine + pasireotide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pentamidine
Ingrezza Sprinkle (valbenazine)

+

pentamidine

1 interaction

Monitor/Modify Tx

valbenazine + pentamidine

monitor ECG; risk may be lower w/ nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pentazocine
Ingrezza Sprinkle (valbenazine)

+

pentazocine

1 interaction

Monitor/Modify Tx

valbenazine + pentazocine

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• perphenazine
Ingrezza Sprinkle (valbenazine)

+

perphenazine

1 interaction

Monitor/Modify Tx

valbenazine + perphenazine

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• posaconazole
Ingrezza Sprinkle (valbenazine)

+

posaconazole

1 interaction

Monitor/Modify Tx

valbenazine + posaconazole

monitor ECG; decr. valbenazine dose to 40 mg qd: combo may incr. valbenazine and active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• pregabalin
Ingrezza Sprinkle (valbenazine)

+

pregabalin

1 interaction

Monitor/Modify Tx

valbenazine + pregabalin

monitor resp. rate: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• procainamide
Ingrezza Sprinkle (valbenazine)

+

procainamide

1 interaction

Monitor/Modify Tx

valbenazine + procainamide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• propafenone
Ingrezza Sprinkle (valbenazine)

+

propafenone

1 interaction

Monitor/Modify Tx

valbenazine + propafenone

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• propofol
Ingrezza Sprinkle (valbenazine)

+

propofol

1 interaction

Monitor/Modify Tx

valbenazine + propofol

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• quazepam
Ingrezza Sprinkle (valbenazine)

+

quazepam

1 interaction

Monitor/Modify Tx

valbenazine + quazepam

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• quinidine (antiarrhythmic)
Ingrezza Sprinkle (valbenazine)

+

quinidine (antiarrhythmic)

1 interaction

Monitor/Modify Tx

valbenazine + quinidine (antiarrhythmic)

monitor quinidine levels, ECG; decr. valbenazine dose to 40 mg qd: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited, additive effects)

• quinine
Ingrezza Sprinkle (valbenazine)

+

quinine

1 interaction

Monitor/Modify Tx

valbenazine + quinine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ranolazine
Ingrezza Sprinkle (valbenazine)

+

ranolazine

1 interaction

Monitor/Modify Tx

valbenazine + ranolazine

monitor ECG: combo may incr. ranolazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)

• remifentanil
Ingrezza Sprinkle (valbenazine)

+

remifentanil

1 interaction

Monitor/Modify Tx

valbenazine + remifentanil

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• remimazolam
Ingrezza Sprinkle (valbenazine)

+

remimazolam

1 interaction

Monitor/Modify Tx

valbenazine + remimazolam

monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• revumenib
Ingrezza Sprinkle (valbenazine)

+

revumenib

1 interaction

Monitor/Modify Tx

valbenazine + revumenib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ribociclib
Ingrezza Sprinkle (valbenazine)

+

ribociclib

1 interaction

Monitor/Modify Tx

valbenazine + ribociclib

monitor ECG, electrolytes; decr. valbenazine dose to 40 mg qd: combo may incr. valbenazine and active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• ritonavir
Ingrezza Sprinkle (valbenazine)

+

ritonavir

1 interaction

Monitor/Modify Tx

valbenazine + ritonavir

monitor ECG; decr. valbenazine dose to 40 mg qd: combo may incr. valbenazine and active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• romidepsin
Ingrezza Sprinkle (valbenazine)

+

romidepsin

1 interaction

Monitor/Modify Tx

valbenazine + romidepsin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• rucaparib
Ingrezza Sprinkle (valbenazine)

+

rucaparib

1 interaction

Monitor/Modify Tx

valbenazine + rucaparib

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• selpercatinib
Ingrezza Sprinkle (valbenazine)

+

selpercatinib

1 interaction

Monitor/Modify Tx

valbenazine + selpercatinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sevoflurane
Ingrezza Sprinkle (valbenazine)

+

sevoflurane

1 interaction

Monitor/Modify Tx

valbenazine + sevoflurane

monitor ECG, resp. rate: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS and resp. depression, psychomotor impairment (additive effects)

• sirolimus
Ingrezza Sprinkle (valbenazine)

+

sirolimus

1 interaction

Monitor/Modify Tx

valbenazine + sirolimus

monitor sirolimus levels: combo may incr. sirolimus levels, risk of serious infection, other adverse effects (P-gp-mediated transport inhibited)

• sufentanil
Ingrezza Sprinkle (valbenazine)

+

sufentanil

1 interaction

Monitor/Modify Tx

valbenazine + sufentanil

monitor resp. rate, decr. sufentanil start dose, consider decr. valbenazine dose, use lowest effective doses: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• suvorexant
Ingrezza Sprinkle (valbenazine)

+

suvorexant

1 interaction

Monitor/Modify Tx

valbenazine + suvorexant

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tacrolimus
Ingrezza Sprinkle (valbenazine)

+

tacrolimus

1 interaction

Monitor/Modify Tx

valbenazine + tacrolimus

monitor tacrolimus levels, ECG, renal fxn: combo may incr. tacrolimus levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects (P-gp-mediated transport inhibited)

• talazoparib
Ingrezza Sprinkle (valbenazine)

+

talazoparib

1 interaction

Monitor/Modify Tx

valbenazine + talazoparib

monitor CBC: combo may incr. talazoparib levels, risk of myelosuppression, other adverse effects (P-gp-mediated transport inhibited)

• tapentadol
Ingrezza Sprinkle (valbenazine)

+

tapentadol

1 interaction

Monitor/Modify Tx

valbenazine + tapentadol

monitor resp. rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• telavancin
Ingrezza Sprinkle (valbenazine)

+

telavancin

1 interaction

Monitor/Modify Tx

valbenazine + telavancin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• temazepam
Ingrezza Sprinkle (valbenazine)

+

temazepam

1 interaction

Monitor/Modify Tx

valbenazine + temazepam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• tenofovir alafenamide
Ingrezza Sprinkle (valbenazine)

+

tenofovir alafenamide

1 interaction

Monitor/Modify Tx

valbenazine + tenofovir alafenamide

if tenofovir alafenamide not admin. w/ cobicistat, monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport inhibited)

• tenofovir disoproxil
Ingrezza Sprinkle (valbenazine)

+

tenofovir disoproxil

1 interaction

Monitor/Modify Tx

valbenazine + tenofovir disoproxil

monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport inhibited)

• terbinafine
Ingrezza Sprinkle (valbenazine)

+

terbinafine

1 interaction

Monitor/Modify Tx

valbenazine + terbinafine

monitor ECG; decr. valbenazine dose to 40 mg qd: combo may incr. valbenazine active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• thiothixene
Ingrezza Sprinkle (valbenazine)

+

thiothixene

1 interaction

Monitor/Modify Tx

valbenazine + thiothixene

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tipranavir
Ingrezza Sprinkle (valbenazine)

+

tipranavir

1 interaction

Monitor/Modify Tx

valbenazine + tipranavir

monitor ECG; decr. valbenazine dose to 40 mg qd: combo may incr. valbenazine and active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• tramadol
Ingrezza Sprinkle (valbenazine)

+

tramadol

1 interaction

Monitor/Modify Tx

valbenazine + tramadol

monitor ECG, resp. rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of QT prolongation, cardiac arrhythmias, profound CNS and resp. depression, psychomotor impairment (additive effects)

• triazolam
Ingrezza Sprinkle (valbenazine)

+

triazolam

1 interaction

Monitor/Modify Tx

valbenazine + triazolam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• triclabendazole
Ingrezza Sprinkle (valbenazine)

+

triclabendazole

1 interaction

Monitor/Modify Tx

valbenazine + triclabendazole

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trifluridine
Ingrezza Sprinkle (valbenazine)

+

trifluridine

1 interaction

Monitor/Modify Tx

valbenazine + trifluridine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• triptorelin
Ingrezza Sprinkle (valbenazine)

+

triptorelin

1 interaction

Monitor/Modify Tx

valbenazine + triptorelin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• tucatinib
Ingrezza Sprinkle (valbenazine)

+

tucatinib

1 interaction

Monitor/Modify Tx

valbenazine + tucatinib

monitor ECG; decr. valbenazine dose to 40 mg qd: combo may incr. valbenazine and active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• ubrogepant
Ingrezza Sprinkle (valbenazine)

+

ubrogepant

1 interaction

Monitor/Modify Tx

valbenazine + ubrogepant

limit ubrogepant dose to 50 mg, may give second 50 mg dose after 2h if needed: combo may incr. ubrogepant levels, risk of adverse effects (P-gp-mediated transport inhibited)

• vemurafenib
Ingrezza Sprinkle (valbenazine)

+

vemurafenib

1 interaction

Monitor/Modify Tx

valbenazine + vemurafenib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• voriconazole
Ingrezza Sprinkle (valbenazine)

+

voriconazole

1 interaction

Monitor/Modify Tx

valbenazine + voriconazole

monitor ECG; decr. valbenazine dose to 40 mg qd: combo may incr. valbenazine and active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• zaleplon
Ingrezza Sprinkle (valbenazine)

+

zaleplon

1 interaction

Monitor/Modify Tx

valbenazine + zaleplon

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ziconotide
Ingrezza Sprinkle (valbenazine)

+

ziconotide

1 interaction

Monitor/Modify Tx

valbenazine + ziconotide

consider decr. dose of one or both drugs: combo may incr. risk of confusion, dizziness, other CNS adverse effects (additive effects)

• zolpidem
Ingrezza Sprinkle (valbenazine)

+

zolpidem

1 interaction

Monitor/Modify Tx

valbenazine + zolpidem

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

Caution Advised

• 5-HTP
Ingrezza Sprinkle (valbenazine)

+

5-HTP

1 interaction

Caution Advised

valbenazine + 5-HTP

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• allopurinol
Ingrezza Sprinkle (valbenazine)

+

allopurinol

1 interaction

Caution Advised

valbenazine + allopurinol

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• almotriptan
Ingrezza Sprinkle (valbenazine)

+

almotriptan

1 interaction

Caution Advised

valbenazine + almotriptan

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• amantadine
Ingrezza Sprinkle (valbenazine)

+

amantadine

1 interaction

Caution Advised

valbenazine + amantadine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• amitriptyline
Ingrezza Sprinkle (valbenazine)

+

amitriptyline

1 interaction

Caution Advised

valbenazine + amitriptyline

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• amoxapine
Ingrezza Sprinkle (valbenazine)

+

amoxapine

1 interaction

Caution Advised

valbenazine + amoxapine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• apraclonidine ophthalmic
Ingrezza Sprinkle (valbenazine)

+

apraclonidine ophthalmic

1 interaction

Caution Advised

valbenazine + apraclonidine ophthalmic

caution advised if apraclonidine IOP adjunct use; postop use OK: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• aripiprazole bimonthly injection
Ingrezza Sprinkle (valbenazine)

+

aripiprazole bimonthly injection

1 interaction

Caution Advised

valbenazine + aripiprazole bimonthly injection

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• aripiprazole lauroxil
Ingrezza Sprinkle (valbenazine)

+

aripiprazole lauroxil

1 interaction

Caution Advised

valbenazine + aripiprazole lauroxil

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• aripiprazole monthly injection
Ingrezza Sprinkle (valbenazine)

+

aripiprazole monthly injection

1 interaction

Caution Advised

valbenazine + aripiprazole monthly injection

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• aripiprazole oral
Ingrezza Sprinkle (valbenazine)

+

aripiprazole oral

1 interaction

Caution Advised

valbenazine + aripiprazole oral

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• baclofen
Ingrezza Sprinkle (valbenazine)

+

baclofen

1 interaction

Caution Advised

valbenazine + baclofen

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• brexpiprazole
Ingrezza Sprinkle (valbenazine)

+

brexpiprazole

1 interaction

Caution Advised

valbenazine + brexpiprazole

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• brimonidine ophthalmic
Ingrezza Sprinkle (valbenazine)

+

brimonidine ophthalmic

1 interaction

Caution Advised

valbenazine + brimonidine ophthalmic

caution advised if elevated IOP use; OTC ocular redness use OK: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• brimonidine topical
Ingrezza Sprinkle (valbenazine)

+

brimonidine topical

1 interaction

Caution Advised

valbenazine + brimonidine topical

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• brivaracetam
Ingrezza Sprinkle (valbenazine)

+

brivaracetam

1 interaction

Caution Advised

valbenazine + brivaracetam

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• bromocriptine
Ingrezza Sprinkle (valbenazine)

+

bromocriptine

1 interaction

Caution Advised

valbenazine + bromocriptine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• brompheniramine
Ingrezza Sprinkle (valbenazine)

+

brompheniramine

1 interaction

Caution Advised

valbenazine + brompheniramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• buspirone
Ingrezza Sprinkle (valbenazine)

+

buspirone

1 interaction

Caution Advised

valbenazine + buspirone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• cannabidiol
Ingrezza Sprinkle (valbenazine)

+

cannabidiol

1 interaction

Caution Advised

valbenazine + cannabidiol

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• cannabis
Ingrezza Sprinkle (valbenazine)

+

cannabis

1 interaction

Caution Advised

valbenazine + cannabis

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• carbinoxamine
Ingrezza Sprinkle (valbenazine)

+

carbinoxamine

1 interaction

Caution Advised

valbenazine + carbinoxamine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• cariprazine
Ingrezza Sprinkle (valbenazine)

+

cariprazine

1 interaction

Caution Advised

valbenazine + cariprazine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• carisoprodol
Ingrezza Sprinkle (valbenazine)

+

carisoprodol

1 interaction

Caution Advised

valbenazine + carisoprodol

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• cetirizine
Ingrezza Sprinkle (valbenazine)

+

cetirizine

1 interaction

Caution Advised

valbenazine + cetirizine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• chamomile, German
Ingrezza Sprinkle (valbenazine)

+

chamomile, German

1 interaction

Caution Advised

valbenazine + chamomile, German

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• chlophedianol
Ingrezza Sprinkle (valbenazine)

+

chlophedianol

1 interaction

Caution Advised

valbenazine + chlophedianol

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• chlorpheniramine
Ingrezza Sprinkle (valbenazine)

+

chlorpheniramine

1 interaction

Caution Advised

valbenazine + chlorpheniramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• chlorzoxazone
Ingrezza Sprinkle (valbenazine)

+

chlorzoxazone

1 interaction

Caution Advised

valbenazine + chlorzoxazone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• clemastine
Ingrezza Sprinkle (valbenazine)

+

clemastine

1 interaction

Caution Advised

valbenazine + clemastine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• clomipramine
Ingrezza Sprinkle (valbenazine)

+

clomipramine

1 interaction

Caution Advised

valbenazine + clomipramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• clozapine
Ingrezza Sprinkle (valbenazine)

+

clozapine

1 interaction

Caution Advised

valbenazine + clozapine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• cyclobenzaprine
Ingrezza Sprinkle (valbenazine)

+

cyclobenzaprine

1 interaction

Caution Advised

valbenazine + cyclobenzaprine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• cyproheptadine
Ingrezza Sprinkle (valbenazine)

+

cyproheptadine

1 interaction

Caution Advised

valbenazine + cyproheptadine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dantrolene
Ingrezza Sprinkle (valbenazine)

+

dantrolene

1 interaction

Caution Advised

valbenazine + dantrolene

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• darifenacin
Ingrezza Sprinkle (valbenazine)

+

darifenacin

1 interaction

Caution Advised

valbenazine + darifenacin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• darolutamide
Ingrezza Sprinkle (valbenazine)

+

darolutamide

1 interaction

Caution Advised

valbenazine + darolutamide

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• desvenlafaxine
Ingrezza Sprinkle (valbenazine)

+

desvenlafaxine

1 interaction

Caution Advised

valbenazine + desvenlafaxine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dexbrompheniramine
Ingrezza Sprinkle (valbenazine)

+

dexbrompheniramine

1 interaction

Caution Advised

valbenazine + dexbrompheniramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dexchlorpheniramine
Ingrezza Sprinkle (valbenazine)

+

dexchlorpheniramine

1 interaction

Caution Advised

valbenazine + dexchlorpheniramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dichlorphenamide
Ingrezza Sprinkle (valbenazine)

+

dichlorphenamide

1 interaction

Caution Advised

valbenazine + dichlorphenamide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• difelikefalin
Ingrezza Sprinkle (valbenazine)

+

difelikefalin

1 interaction

Caution Advised

valbenazine + difelikefalin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• difenoxin
Ingrezza Sprinkle (valbenazine)

+

difenoxin

1 interaction

Caution Advised

valbenazine + difenoxin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dimenhydrinate
Ingrezza Sprinkle (valbenazine)

+

dimenhydrinate

1 interaction

Caution Advised

valbenazine + dimenhydrinate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• diphenhydramine
Ingrezza Sprinkle (valbenazine)

+

diphenhydramine

1 interaction

Caution Advised

valbenazine + diphenhydramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• diphenoxylate
Ingrezza Sprinkle (valbenazine)

+

diphenoxylate

1 interaction

Caution Advised

valbenazine + diphenoxylate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• doxepin
Ingrezza Sprinkle (valbenazine)

+

doxepin

1 interaction

Caution Advised

valbenazine + doxepin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• doxepin topical
Ingrezza Sprinkle (valbenazine)

+

doxepin topical

1 interaction

Caution Advised

valbenazine + doxepin topical

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dronabinol
Ingrezza Sprinkle (valbenazine)

+

dronabinol

1 interaction

Caution Advised

valbenazine + dronabinol

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• duloxetine
Ingrezza Sprinkle (valbenazine)

+

duloxetine

1 interaction

Caution Advised

valbenazine + duloxetine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• eletriptan
Ingrezza Sprinkle (valbenazine)

+

eletriptan

1 interaction

Caution Advised

valbenazine + eletriptan

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• entacapone
Ingrezza Sprinkle (valbenazine)

+

entacapone

1 interaction

Caution Advised

valbenazine + entacapone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• entrectinib
Ingrezza Sprinkle (valbenazine)

+

entrectinib

1 interaction

Caution Advised

valbenazine + entrectinib

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• escitalopram
Ingrezza Sprinkle (valbenazine)

+

escitalopram

1 interaction

Caution Advised

valbenazine + escitalopram

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• eslicarbazepine acetate
Ingrezza Sprinkle (valbenazine)

+

eslicarbazepine acetate

1 interaction

Caution Advised

valbenazine + eslicarbazepine acetate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ethosuximide
Ingrezza Sprinkle (valbenazine)

+

ethosuximide

1 interaction

Caution Advised

valbenazine + ethosuximide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• felbamate
Ingrezza Sprinkle (valbenazine)

+

felbamate

1 interaction

Caution Advised

valbenazine + felbamate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• fenfluramine
Ingrezza Sprinkle (valbenazine)

+

fenfluramine

1 interaction

Caution Advised

valbenazine + fenfluramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• fesoterodine
Ingrezza Sprinkle (valbenazine)

+

fesoterodine

1 interaction

Caution Advised

valbenazine + fesoterodine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• flibanserin
Ingrezza Sprinkle (valbenazine)

+

flibanserin

1 interaction

Caution Advised

valbenazine + flibanserin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• fluvoxamine
Ingrezza Sprinkle (valbenazine)

+

fluvoxamine

1 interaction

Caution Advised

valbenazine + fluvoxamine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• foslevodopa
Ingrezza Sprinkle (valbenazine)

+

foslevodopa

1 interaction

Caution Advised

valbenazine + foslevodopa

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• frovatriptan
Ingrezza Sprinkle (valbenazine)

+

frovatriptan

1 interaction

Caution Advised

valbenazine + frovatriptan

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ganaxolone
Ingrezza Sprinkle (valbenazine)

+

ganaxolone

1 interaction

Caution Advised

valbenazine + ganaxolone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• glecaprevir
Ingrezza Sprinkle (valbenazine)

+

glecaprevir

1 interaction

Caution Advised

valbenazine + glecaprevir

caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• glofitamab
Ingrezza Sprinkle (valbenazine)

+

glofitamab

1 interaction

Caution Advised

valbenazine + glofitamab

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• glycopyrrolate
Ingrezza Sprinkle (valbenazine)

+

glycopyrrolate

1 interaction

Caution Advised

valbenazine + glycopyrrolate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• guanfacine
Ingrezza Sprinkle (valbenazine)

+

guanfacine

1 interaction

Caution Advised

valbenazine + guanfacine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• hyoscyamine
Ingrezza Sprinkle (valbenazine)

+

hyoscyamine

1 interaction

Caution Advised

valbenazine + hyoscyamine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• iloperidone
Ingrezza Sprinkle (valbenazine)

+

iloperidone

1 interaction

Caution Advised

valbenazine + iloperidone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• imipramine
Ingrezza Sprinkle (valbenazine)

+

imipramine

1 interaction

Caution Advised

valbenazine + imipramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lacosamide
Ingrezza Sprinkle (valbenazine)

+

lacosamide

1 interaction

Caution Advised

valbenazine + lacosamide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lamotrigine
Ingrezza Sprinkle (valbenazine)

+

lamotrigine

1 interaction

Caution Advised

valbenazine + lamotrigine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lasmiditan
Ingrezza Sprinkle (valbenazine)

+

lasmiditan

1 interaction

Caution Advised

valbenazine + lasmiditan

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• levetiracetam
Ingrezza Sprinkle (valbenazine)

+

levetiracetam

1 interaction

Caution Advised

valbenazine + levetiracetam

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• levocetirizine
Ingrezza Sprinkle (valbenazine)

+

levocetirizine

1 interaction

Caution Advised

valbenazine + levocetirizine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• levodopa
Ingrezza Sprinkle (valbenazine)

+

levodopa

1 interaction

Caution Advised

valbenazine + levodopa

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• levomilnacipran
Ingrezza Sprinkle (valbenazine)

+

levomilnacipran

1 interaction

Caution Advised

valbenazine + levomilnacipran

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• loxapine
Ingrezza Sprinkle (valbenazine)

+

loxapine

1 interaction

Caution Advised

valbenazine + loxapine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lumateperone
Ingrezza Sprinkle (valbenazine)

+

lumateperone

1 interaction

Caution Advised

valbenazine + lumateperone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lurasidone
Ingrezza Sprinkle (valbenazine)

+

lurasidone

1 interaction

Caution Advised

valbenazine + lurasidone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• meclizine
Ingrezza Sprinkle (valbenazine)

+

meclizine

2 interactions

Caution Advised

valbenazine + meclizine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• melatonin
Ingrezza Sprinkle (valbenazine)

+

melatonin

2 interactions

Caution Advised

valbenazine + melatonin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• meprobamate
Ingrezza Sprinkle (valbenazine)

+

meprobamate

2 interactions

Caution Advised

valbenazine + meprobamate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• methocarbamol
Ingrezza Sprinkle (valbenazine)

+

methocarbamol

2 interactions

Caution Advised

valbenazine + methocarbamol

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• methsuximide
Ingrezza Sprinkle (valbenazine)

+

methsuximide

2 interactions

Caution Advised

valbenazine + methsuximide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• methyldopa
Ingrezza Sprinkle (valbenazine)

+

methyldopa

2 interactions

Caution Advised

valbenazine + methyldopa

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• metyrapone
Ingrezza Sprinkle (valbenazine)

+

metyrapone

2 interactions

Caution Advised

valbenazine + metyrapone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• metyrosine
Ingrezza Sprinkle (valbenazine)

+

metyrosine

2 interactions

Caution Advised

valbenazine + metyrosine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• milnacipran
Ingrezza Sprinkle (valbenazine)

+

milnacipran

2 interactions

Caution Advised

valbenazine + milnacipran

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• molindone
Ingrezza Sprinkle (valbenazine)

+

molindone

2 interactions

Caution Advised

valbenazine + molindone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• mosunetuzumab
Ingrezza Sprinkle (valbenazine)

+

mosunetuzumab

2 interactions

Caution Advised

valbenazine + mosunetuzumab

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• mycophenolate mofetil
Ingrezza Sprinkle (valbenazine)

+

mycophenolate mofetil

2 interactions

Caution Advised

valbenazine + mycophenolate mofetil

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• naldemedine
Ingrezza Sprinkle (valbenazine)

+

naldemedine

2 interactions

Caution Advised

valbenazine + naldemedine

caution advised: combo may incr. naldemedine levels, risk of adverse effects (P-gp-mediated transport inhibited)

• naltrexone
Ingrezza Sprinkle (valbenazine)

+

naltrexone

1 interaction

Caution Advised

valbenazine + naltrexone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• naratriptan
Ingrezza Sprinkle (valbenazine)

+

naratriptan

2 interactions

Caution Advised

valbenazine + naratriptan

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• nortriptyline
Ingrezza Sprinkle (valbenazine)

+

nortriptyline

2 interactions

Caution Advised

valbenazine + nortriptyline

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• oxcarbazepine
Ingrezza Sprinkle (valbenazine)

+

oxcarbazepine

2 interactions

Caution Advised

valbenazine + oxcarbazepine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• passion flower
Ingrezza Sprinkle (valbenazine)

+

passion flower

2 interactions

Caution Advised

valbenazine + passion flower

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• perampanel
Ingrezza Sprinkle (valbenazine)

+

perampanel

2 interactions

Caution Advised

valbenazine + perampanel

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• pheniramine
Ingrezza Sprinkle (valbenazine)

+

pheniramine

2 interactions

Caution Advised

valbenazine + pheniramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• pibrentasvir
Ingrezza Sprinkle (valbenazine)

+

pibrentasvir

2 interactions

Caution Advised

valbenazine + pibrentasvir

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

• pramipexole
Ingrezza Sprinkle (valbenazine)

+

pramipexole

2 interactions

Caution Advised

valbenazine + pramipexole

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• prochlorperazine
Ingrezza Sprinkle (valbenazine)

+

prochlorperazine

1 interaction

Caution Advised

valbenazine + prochlorperazine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• protriptyline
Ingrezza Sprinkle (valbenazine)

+

protriptyline

1 interaction

Caution Advised

valbenazine + protriptyline

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• pyrilamine
Ingrezza Sprinkle (valbenazine)

+

pyrilamine

1 interaction

Caution Advised

valbenazine + pyrilamine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• quetiapine
Ingrezza Sprinkle (valbenazine)

+

quetiapine

2 interactions

Caution Advised

valbenazine + quetiapine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ramelteon
Ingrezza Sprinkle (valbenazine)

+

ramelteon

1 interaction

Caution Advised

valbenazine + ramelteon

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• risperidone
Ingrezza Sprinkle (valbenazine)

+

risperidone

1 interaction

Caution Advised

valbenazine + risperidone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• rizatriptan
Ingrezza Sprinkle (valbenazine)

+

rizatriptan

1 interaction

Caution Advised

valbenazine + rizatriptan

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ropeginterferon alfa-2b
Ingrezza Sprinkle (valbenazine)

+

ropeginterferon alfa-2b

1 interaction

Caution Advised

valbenazine + ropeginterferon alfa-2b

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ropinirole
Ingrezza Sprinkle (valbenazine)

+

ropinirole

1 interaction

Caution Advised

valbenazine + ropinirole

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• rotigotine transdermal
Ingrezza Sprinkle (valbenazine)

+

rotigotine transdermal

1 interaction

Caution Advised

valbenazine + rotigotine transdermal

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• rufinamide
Ingrezza Sprinkle (valbenazine)

+

rufinamide

1 interaction

Caution Advised

valbenazine + rufinamide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• scopolamine
Ingrezza Sprinkle (valbenazine)

+

scopolamine

1 interaction

Caution Advised

valbenazine + scopolamine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• selinexor
Ingrezza Sprinkle (valbenazine)

+

selinexor

1 interaction

Caution Advised

valbenazine + selinexor

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• sertraline
Ingrezza Sprinkle (valbenazine)

+

sertraline

1 interaction

Caution Advised

valbenazine + sertraline

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• solifenacin
Ingrezza Sprinkle (valbenazine)

+

solifenacin

1 interaction

Caution Advised

valbenazine + solifenacin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• stiripentol
Ingrezza Sprinkle (valbenazine)

+

stiripentol

1 interaction

Caution Advised

valbenazine + stiripentol

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• sumatriptan
Ingrezza Sprinkle (valbenazine)

+

sumatriptan

1 interaction

Caution Advised

valbenazine + sumatriptan

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tasimelteon
Ingrezza Sprinkle (valbenazine)

+

tasimelteon

1 interaction

Caution Advised

valbenazine + tasimelteon

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• thiotepa
Ingrezza Sprinkle (valbenazine)

+

thiotepa

1 interaction

Caution Advised

valbenazine + thiotepa

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tiagabine
Ingrezza Sprinkle (valbenazine)

+

tiagabine

1 interaction

Caution Advised

valbenazine + tiagabine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tizanidine
Ingrezza Sprinkle (valbenazine)

+

tizanidine

1 interaction

Caution Advised

valbenazine + tizanidine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tolcapone
Ingrezza Sprinkle (valbenazine)

+

tolcapone

1 interaction

Caution Advised

valbenazine + tolcapone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tolterodine
Ingrezza Sprinkle (valbenazine)

+

tolterodine

1 interaction

Caution Advised

valbenazine + tolterodine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• topiramate
Ingrezza Sprinkle (valbenazine)

+

topiramate

1 interaction

Caution Advised

valbenazine + topiramate

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• trazodone
Ingrezza Sprinkle (valbenazine)

+

trazodone

1 interaction

Caution Advised

valbenazine + trazodone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• trifluoperazine
Ingrezza Sprinkle (valbenazine)

+

trifluoperazine

1 interaction

Caution Advised

valbenazine + trifluoperazine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• trihexyphenidyl
Ingrezza Sprinkle (valbenazine)

+

trihexyphenidyl

1 interaction

Caution Advised

valbenazine + trihexyphenidyl

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• trimipramine
Ingrezza Sprinkle (valbenazine)

+

trimipramine

1 interaction

Caution Advised

valbenazine + trimipramine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• triprolidine
Ingrezza Sprinkle (valbenazine)

+

triprolidine

1 interaction

Caution Advised

valbenazine + triprolidine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• trospium
Ingrezza Sprinkle (valbenazine)

+

trospium

1 interaction

Caution Advised

valbenazine + trospium

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• valerian
Ingrezza Sprinkle (valbenazine)

+

valerian

1 interaction

Caution Advised

valbenazine + valerian

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• valproic acid
Ingrezza Sprinkle (valbenazine)

+

valproic acid

1 interaction

Caution Advised

valbenazine + valproic acid

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• venlafaxine
Ingrezza Sprinkle (valbenazine)

+

venlafaxine

1 interaction

Caution Advised

valbenazine + venlafaxine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• vigabatrin
Ingrezza Sprinkle (valbenazine)

+

vigabatrin

1 interaction

Caution Advised

valbenazine + vigabatrin

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• vilazodone
Ingrezza Sprinkle (valbenazine)

+

vilazodone

1 interaction

Caution Advised

valbenazine + vilazodone

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• viloxazine
Ingrezza Sprinkle (valbenazine)

+

viloxazine

1 interaction

Caution Advised

valbenazine + viloxazine

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• zolmitriptan
Ingrezza Sprinkle (valbenazine)

+

zolmitriptan

1 interaction

Caution Advised

valbenazine + zolmitriptan

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• zonisamide
Ingrezza Sprinkle (valbenazine)

+

zonisamide

1 interaction

Caution Advised

valbenazine + zonisamide

caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)